On August 21, EVEREST MED fell 6.77% in regular trading, trading at approximately 31.34 HKD per share, with turnover of 67.08 million HKD. The decline reflects clear profit-taking following the stock's extraordinary 41.43% gain in the prior session.

On August 20, the stock surged as much as 89% intraday after Moderna and Merck announced their mRNA personalized cancer vaccine intismeran autogene achieved positive results in a pivotal Phase 3 trial for high-risk melanoma patients. Simultaneously, EVEREST MED reported strong interim results with revenue of RMB 1.148 billion, up 157% year-over-year, and net losses narrowing 97.62% to just RMB 5.944 million, approaching breakeven. The dual catalysts drove massive volume of HKD 980 million on August 20.

Today's pullback reflects typical post-surge consolidation as short-term traders locked in gains. Peer CANSINOBIO also declined 3.31% on the same day, indicating broad cooling across the mRNA concept space. Bocom International maintained a Buy rating with a target price of 66 HKD, though it trimmed revenue forecasts by 15-18% citing intensifying competition for core product Nefecon and supply constraints for Xerava.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)